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Abstract
Supplementary to the efficient inhibition of trypsin, chymo-
trypsin, plasma kallikrein, and plasmin already described by
the EcTI inhibitor from Enterolobium contortisiliquum, it
also blocks human neutrophil elastase (Kiapps4.3 nM) and
prevents phorbol ester (PMA)-stimulated activation of matrix
metalloproteinase (MMP)-2 probably via interference with
membrane-type 1 (MT1)-MMP. Moreover, plasminogen-
induced activation of proMMP-9 and processing of active
MMP-2 was also inhibited. Furthermore, the effect of EcTI
on the human cancer cell lines HCT116 and HT29 (colorec-
tal), SkBr-3 and MCF-7 (breast), K562 and THP-1 (leuke-
mia), as well as on human primary fibroblasts and human
mesenchymal stem cells (hMSCs) was studied. EcTI inhib-
ited in a concentration range of 1.0–2.5 mM rather specifi-
cally tumor cell viability without targeting primary
fibroblasts and hMSCs. Taken together, our data indicate that
the polyspecific proteinase inhibitor EcTI prevents proMMP
activation and is cytotoxic against tumor cells without affect-
ing normal tissue remodeling fibroblasts or regenerative
hMSCs being an important tool in the studies of tumor cell
development and dissemination.
Keywords: cancer; Kunitz inhibitors; matrix
metalloproteinases; mesenchymal stem cells; plant
proteinases.
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Introduction
Pathobiological events such as tumor progression include a
complex network of proteinases and their inhibitors that
affect different cellular signaling processes interfering direct-
ly or indirectly with cellular receptors (Hoekstra et al., 2001;
Jedeszko and Sloane, 2004; Nagase et al., 2006; Lopez-Otin
and Matrisian, 2007). The importance of proteinase activity
for the enhancement of malignant tumor cell invasion and
metastasis formation as a major cause of death in cancer
patients has been studied extensively demonstrating that pro-
teolysis-supported invasiveness, growth and movement of
tumor cells are important characteristics contributing to
malignancy (Woodhouse et al., 1997; Koblinski et al., 2000;
Liotta and Clair, 2000; Nguyen, 2004; Duffy et al., 2008).
Thereby, the extracellular matrix (ECM) plays a major role
as a physical barrier that migrating cells have to surpass. The
composition of the ECM, its three-dimensional organization
and proteolytic remodeling are relevant determinants of
microenvironmental signaling that controls cell shape, motil-
ity, growth, survival, and differentiation of stromal and tumor
cells as well (Werb, 1997; Lukashev and Werb, 1998; Ger-
manov et al., 2006; Wolf and Friedl, 2006; Bidard et al.,
2008). As shown recently, ECM is substantially modified by
proteinases produced by tumor or stromal cells resulting in
the alteration of cell-cell and cell-matrix interactions which
can, therefore, be prevented by application of effective pro-
teinase inhibitors (DeClerck et al., 2004; Ohkoshi and Sasa-
ki, 2005; Lah et al., 2006; Turk, 2006).
Among the numerous proteinases being responsible for
ECM degradation, matrix metalloproteinases (MMPs) appear
to be primarily involved in the initial step of this process.
Based on their structure and substrate specificity, MMPs can
be subdivided into main evolutionary groups: collagenases,
gelatinases, stromelysins, membrane-type metallopeptidases
(MT-MMP), and others (Nagase and Woessner, 1999; Nagase
et al., 2006; Lazar et al., 2010).
Described as multifunctional enzymes capable of cleaving
the ECM components (collagens, laminin, fibronectin, vitro-
nectin, aggrecan, enactin, versican, perlecan, tenascin, elas-
tin, and many others), these peptidases can affect cell
proliferation, adhesion, migration, and invasion, as well as
angiogenesis and metastasis, not only by degradation of the
ECM, but also by the release of sequestered growth factors
or the generation of bioactive fragments and degradation of
functional proteins involved in cell-cell and cell-ECM inter-
actions (Noel et al., 2008). Various studies correlate the high
expression of MMP with the metastatic potential of tumors
and poor survival in lung, prostate, stomach, colon, breast,
ovary, pancreatic, oral squamous cell cancers, and other can-
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Figure 1 Enterolobium contortisiliquum fruit with the seeds.
The bar corresponds to 23 cm.
cers (Liu et al., 2007). In this regard, especially MMP-2 and
MMP-9 (gelatinase A and gelatinase B, respectively) are
known to degrade collagen type IV, the major component of
basement membranes (Turpeenniemi-Hujanen, 2005; Fingle-
ton, 2007). This assumption has been confirmed by many
investigations correlating increased expression and activity
of these gelatinases with poor prognosis and decreased sur-
vival of cancer patients (Stearns and Stearns, 1996; Kalla-
kury et al., 2001; Bjorklund and Koivunen, 2005; Martin and
Matrisian, 2007).
Because of their high degrading activity and potentially
disastrous effect on the cell microenvironment, cellular
MMPs are expressed in small amounts, and their cellular
localization and activity are tightly controlled, either posi-
tively or negatively (Sternlicht and Werb, 2001; Zucker et
al., 2003). For example, the pro-invasive, membrane-type 1
(MT1)-MMP (MMP-14), a major mediator of pericellular
proteolytic events in cancer cells by cleaving ECM proteins,
initiating activation of soluble MMPs and controls the func-
tionality of cell adhesion (Egeblad and Werb, 2002; Seiki,
2003; Itoh and Seiki, 2006; Barbolina and Stack, 2008) is
synthesized as a zymogen that requires proteolytic processing
of the N-terminal inhibitory prodomain (Golubkov et al.,
2010; Roghi et al., 2010). Once activated, MT1-MMP can
be inhibited by its physiological inhibitors, tissue inhibitors
of metalloproteinases-2, -3, and -4 (TIMP-2, -3, and -4) (Will
et al., 1996; Brew and Nagase, 2010). MT1-MMP, as
opposed to the soluble MMPs, is ideally positioned to reg-
ulate pericellular proteolysis and the functionality of cell
receptors (Kessenbrock et al., 2010).
Through receptor-mediated signaling, MMPs can be acti-
vated by other peptidases that contribute to tumor formation,
or influence the cellular microenvironment, tumor initiation
and progression. For instance, the serine proteinase plasmin
does not only degrade ECM components but is also an effi-
cient activator of proMMP-3, which in turn activates
proMMP-9 by sequential cleavage of the Glu40-Met41 and
Arg87-Phe88 bonds (Murphy and Crabbe, 1995). In addition,
plasmin contributes to direct activation of proMMP-9 as well
as of proMMP-2 and proMMP-13 (Baramova et al., 1997).
Similarly, human tumor-associated trypsin-2 is an efficient
activator of proMMP-9 (Sorsa et al., 1997) and chymotryp-
sin-like proteinases have also been reported to activate
proMMP-9 (Han et al., 2002) pointing to an extended inter-
play between serine proteinases and MMPs.
Furthermore, cysteine proteinases are also involved in this
network, as demonstrated by functional imaging of tumor
proteolysis (Sloane et al., 2006). These increased proteinase
activities detected in tumor tissues confirm the importance
of the proteolytic network for the development of cancer and
indicate that tumor cell invasion and metastasis are facilitated
by uncontrolled interactions between proteolytic enzymes
(Moll et al., 1990; Leipner and Saller, 2000; Skrzydlewska
et al., 2005; Sloane et al., 2006). Hence, inhibition of extra-
cellular released proteinases could be an attractive approach
for cancer therapy (Lah et al., 2006; Turk, 2006). Consid-
ering the complex proteinase network, an inhibitor able to
interfere with more than one target enzyme could be useful
for studies of tumor progression. In this direction, the action
of the Enterolobium contortisiliquum trypsin inhibitor
(EcTI), a potent polyspecific Kunitz-type inhibitor (Batista
et al., 1996) was evaluated compared with the chemothera-
peutic drug 5-fluorouracil (5-FU) (Diasio and Johnson, 2000)
on cell viability of colorectal, breast, leukemic tumor cell
lines compared with the effect on fibroblast and mesenchy-
mal stem cells.
Results
Proteinase inhibition
Using a modified biochemical approach for protein purifi-
cation, we achieved enough material for further characteri-
zation of the Kunitz-type inhibitor EcTI from seeds of the
Brazilian plant E. contortisiliquum (Figure 1). The inhibitor
homogeneity was assessed by a reverse phase chromatogra-
phy with acetonitrile gradient (Figure 2) and by SDS-PAGE
(Figure 2, insert), in which it appears, in a reducing condi-
tion, as a double polypeptide chains protein with molecular
masses of 16 kDa and 4.0 kDa, respectively. EcTI purity was
also confirmed by N-terminal sequence determination and by
mass spectrometry. The 20 kDa inhibitor was shown to block
the activity of trypsin, chymotrypsin, plasma kallikrein, and
plasmin (Table 1) as previously described (Batista et al.,
1996). Here, we analyzed the effect of EcTI on human neu-
trophil elastase (HNE) that was inhibited with a Kiapp of
55 nM (Table 1).
Owing to the effect of EcTI on plasmin activity, we inves-
tigated if the cell-associated proMMP activation was influ-
enced by EcTI in comparison to BbCI (an inhibitor of
elastase and cysteine proteinases) and BbKl (a kallikrein
inhibitor), as well as to the general serine proteinase inhibitor
aprotinin. Similar to EcTI, both BbCI and BbKI were iso-
lated from plant seeds (de Oliveira et al., 2001; Oliva et al.,
2001), whereas aprotinin is derived from animal tissue (Fritz
and Wunderer, 1983). HT1080 fibrosarcoma cells were used
as a cell model, because these cells are known to express
proMMP-9, proMMP-2, and MT1-MMP which is required
for proMMP-2 activation on the cell surface (Moll et al.,
1990; Stanton et al., 1998). Zymographic analysis of
HT1080 culture supernatants demonstrated constitutive
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Figure 2 Reversed-phase (RP) chromatography.
RP chromatography was performed on a C18 column equilibrated with 0.1% TFA and developed with an acetonitrile gradient (0–100%)
in TFA; the flow rate was 0.5 ml/min. Sample: EcTI (400 mg) after size exclusion chromatography on Superdex 75. Inset: SDS-PAGE
analysis of purified forms of EcTI. Reducing condition, as a two-polypeptide chain protein with molecular masses of 16 kDa and 4.0 kDa,
respectively (lane A); EcTI: 20 kDa (lane B); molecular mass standards (lane C).
secretion of proMMP-9 (;94 kDa) and proMMP-2
(;72 kDa) together with low amounts of active MMP-2
(;66 kDa). Addition of PMA to the cells enhanced the
release of proMMP-9 from the cells and increased the for-
mation of active 66-kDa MMP-2 (Figure 3). These findings
are in agreement with previous results obtained from
HT1080 cells (Moll et al., 1990; Baramova et al., 1997).
Remarkably, the co-incubation of HT1080 with EcTI com-
pletely blocked PMA-stimulated proMMP-2 activation in
contrast to BbCI, BbKI, and aprotinin which had no similar
effect (Figure 3), indicating an interference of EcTI with
MT1-MMP-mediated activation of proMMP-2. As deter-
mined by the trypan blue exclusion test, cell viability was
not affected at inhibitor concentrations of 1 mM used in the
experiments.
Furthermore, we analyzed whether HT1080 incubation
with plasminogen as a source for uPA/PAR-dependent cell-
associated formation of plasmin would influence proMMP
activation. Plasmin is known for its ability to convert the 66-
kDa intermediate active form of proMMP-2 into mature 64-
kDa MMP-2 (Baramova et al., 1997). In addition, plasmin
can activate proMMP-9 (Ramos-DeSimone et al., 1999).
Plasminogen alone or in combination with PMA led to the
disappearance of 66-kDa MMP-2 and emergence of 64-kDa
MMP-2 in HT1080 culture supernatants as shown by zymo-
graphy (Figure 3). Addition of EcTI abolished the generation
of 66-kDa and 64-kDa MMP-2 in plasminogen/PMA-treated
cells, whereas BbCI and BbKI had no effect. Although apro-
tinin also did not prevent proMMP-2 activation to the inter-
mediate active 66-kDa form, it successfully inhibited a
further presumably plasmin-mediated conversion to the 64-
kDa active MMP-2. Moreover, exposition of HT1080 cells
to plasminogen enabled activation of proMMP-9 into 82-kDa
MMP-9 both in the absence and presence of PMA. This
process was slightly decreased by EcTI, but was unaffected
by BbCI or BbKI. Because aprotinin, a potent plasmin inhib-
itor, efficiently blocked proMMP-9 activation under these
conditions, the EcTI effect in this process is probably as a
result of inhibition of plasmin.
Reduction of cell viability
The effect of EcTI on the viability of human tumor cell lines
and primary cells with regenerative capacity such as human
fibroblasts was analyzed by the MTS assay which allows the
detection of metabolically intact cells. In addition, the effect
of EcTI was compared with that of 5-FU as a well-known
clinically applied cell-toxic agent. As demonstrated in Figure
4, the antimetabolic influence of 5-FU on most tumor cell
lines did not vary significantly by increasing its concentra-
tion from 1 mM to 12.5 mM. 5-FU shows reduction of tumor
cell viability between 11% and 56% depending on the tested
cell lines after 24 h incubation time. The toxic influence of
the chemotherapeutic agent increased up to 79% on K562
and THP1 lines at 48 h incubation. By contrast, EcTI exhib-
its a significant concentration-dependent cell-toxic effect on
tumor cell lines. The reduction of cell viability varied
approximately between 13% and 84% already after 24 h
incubation time and increased slightly up to 85% at 48 h
(Figure 4).
Although EcTI shows reduction of tumor cell viability,
primary fibroblast metabolism was not impaired, at least at
concentrations below 50 mM (Figure 5). Indeed, on primary
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Table 1 Inhibitory properties of EcTI.
Mammalian serine proteinase Kiapp
Bovine trypsin 0.88
Bovine chymotrypsin 1.11
Bovine pancreatic elastase n.i.
Human neutrophil elastase 55
Human plasma kallikrein 6.1
Human factor Xa n.i.
Human plasmin 9.36
Porcine pancreatic kallikrein n.i.
‘n.i.’: no detectable inhibition. Inhibitor and proteinase were
incubated at 378C with one of the following proteinases and
respective substrates: trypsin (7.0 nM in 0.05 M Tris-HCl, pH
8.0, 0.02% CaCl2; 1.0 mM BAPA), chymotrypsin (76 nM in
0.1 M Tris-HCl, pH 8.0, 0.02% CaCl2; 2.0 mM Suc-Phe-
pNan), HuPK, human plasma kallikrein (67 nM in 0.05 M
Tris-HCl, pH 8.0; 0.5 mM H-D-Pro-Phe-Arg-pNan); PoPK,
porcine pancreatic kallikrein (2.6 nM in 0.1 M Tris-HCl, pH
8.0; 0.8 mM Ac-Phe-Arg-pNan), PPE, porcine pancreatic
elastase (71 nM in 0.05 M Tris-HCl, pH 8.0, 0.5 M NaCl;
0.5 mM MeO-Suc-Ala-Ala-Pro-Val-pNan), HNE, human
neutrophil elastase (25 nM in 0.05 M Tris-HCl, pH 7.0, 0.5 M
NaCl; 0.5 mM MeO-Suc-Ala-Ala-Pro-Val-pNan), factor Xa
(56 nM in Tris-HCl 0.05 M, pH 8.0; 1.5 mM Boc-Ile-Glu-
Gly-Arg-AMC), and plasmin (3.5 nM in 0.1 M Tris-HCl,
0.2 M NaCl, pH 7.4; 1.0 mM H-D-Val-Leu-Lys-pNan). Kiapp
values were determined by adjusting the experimental points
to the equation for tight binding, using nonlinear regression
with the Grafit program (Morrison, 1982).
Figure 3 Effect of EcTI on the activation of proMMP-9 and proMMP-2 induced by plasminogen and/or PMA.
HT1080 cells were incubated in the absence and presence of PMA (25 ng/ml), plasminogen (10 mg/ml) and the serine proteinase inhibitors
BbCI (BC), BbKI (BK), EcTI (ET), or aprotinin (1 mM each). After 48 h culture, supernatants were collected and analyzed for the presence
of (pro)MMP-9 and (pro)MMP-2 forms using gelatin zymography.
human mesenchymal stem cells (hMSCs), EcTI in a concen-
tration of 10 mM or 100 mM, even after 7 days incubation
did not affect cell proliferation as measured by binding of a
fluorescent dye to cellular nucleic acids differing from 5-FU,
whereas 10 mM 5-FU blocked hMSC proliferation up to 80%
(Figure 6).
Discussion
A disturbed interaction of proteinases and their inhibitors
seems to be the main reason for enhanced tumor cell migra-
tion and invasion of healthy tissue, leading to metastasis for-
mation and eventually organ destruction. This assumption is
based on the fact that the failure of endogenous inhibitors to
counterbalance overwhelming destructive proteinase activi-
ties has been shown to correlate with the progression of var-
ious tumor entities such as breast, colon cancer, or leukemia
(Skrzydlewska et al., 2005; Sloane et al., 2006; Bhoola et
al., 2007). Therefore, the search for effective inhibitors appli-
cable in such clinical situations was and still is a challenging
topic of tumor therapy-relevant research (Lah et al., 2006;
Turk, 2006).
In recent years, many proteinase inhibitors have been
found in plants, especially in legume seeds (Nakahata et al.,
2006; Oliva and Sampaio, 2008; Roy and Dutta, 2009;
Macedo et al., 2010; Prasad et al., 2010). One major aspect
of interest in plant-derived inhibitors is to discover the rela-
tionship of structure and specificity or selectivity of these
inhibitors for different proteinases enabling structural modi-
fications to target a variety of proteinases, which are signif-
icantly involved in tumor development. Thereby, not only
growth and migration of tumor cells (Woodhouse et al.,
1997; Koblinski et al., 2000; Park et al., 2000) but also their
adhesion capacity and cell metabolism (Miyasaka, 1995;
Braga, 2000; Fashena and Thomas, 2000; Parise et al., 2000;
Gocheva and Joyce, 2007) should be affected to eliminate
malignant diseases.
The trypsin inhibitor, EcTI, purified from the seeds of the
Leguminosae E. contortisiliquum was previously character-
ized as a polyspecific 20 kDa serine proteinase inhibitor that
inhibits the digestion enzymes trypsin and chymotrypsin, in
addition to plasma kallikrein and plasmin which are involved
in the intrinsic pathway of blood clotting and fibrinolysis,
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Figure 4 Effects of 5-FU or EcTI or 5-FUqEcTI on the human cancer cell lines HCT116 and HT29 (colorectal), SkBr-3 and MCF-7
(breast), K562 and THP-1 (leukemia).
The cells were incubated for 24 h and thereafter treated with increasing drug concentrations for a further 24 h and 48 h. Cell viability was
measured with the MTS assay evaluating the bioreduction of MTS into a water soluble formazan; EcTI *p-0.05 vs. 5-FU plus EcTI.
respectively (Batista et al., 1996; Oliva and Sampaio, 2009).
In the present study, we focused on the action of EcTI on
neutrophil and pancreatic elastase as well as on the activation
of MMPs. Furthermore, the influence of EcTI on the metab-
olism or proliferation of human tumor cell lines, fibroblasts,
and hMSCs was studied.
As demonstrated here, EcTI does not target porcine pan-
creatic elastase but efficiently inhibits purified HNE.
Because HNE is well-known to disintegrate ECM proteins
and to inactivate endogenous serine proteinase inhibitors
such as a2-antiplasmin and PAI-1, the main inhibitors of the
fibrinolytic system, the enzyme might readily contribute to
uncontrolled proteinase activities and thus to tumor cell inva-
sion and metastasis in vivo (Hildenbrand et al., 2008). HNE
can promote the adhesion of neutrophils and tumor cells to
vascular endothelial cells thereby further facilitating tumor
metastasis (Nozawa et al., 2000). Interestingly, HNE is pro-
duced not only by neutrophils but also by diverse cancer cell
lines, in particular by breast cancer cells (Sun and Yang,
2004; Sato et al., 2006). Although the main origin of HNE
in tumor tissue extracts is, therefore, not yet clear, extended
measurement of HNE in human breast cancer tissue samples
revealed a distinct correlation between elevated elastase lev-
els, breast cancer metastasis, and poor prognosis of the
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Figure 5 Effects of EcTI on cell viability of primary fibroblasts.
The cells were incubated for 24 h and then treated with increasing concentration of EcTI for a further 24 h and 48 h. Cell viability was
measured with the MTS assay evaluating the bioreduction of MTS into a water soluble formazan; EcTI *p-0.05 vs. 5-FU plus EcTI.
Figure 6 Effects of EcTI or 5-FU on cell proliferation of hMSCs.
hMSCs were preincubated for 24 h and then treated with 10 mM
and 100 mM 5-FU or EcTI for further 7 days. Cell proliferation was
measured by binding of a fluorescent dye to cellular nucleic acids
using the CyQuant assay.
patients (Foekens et al., 2003a). Furthermore, increased elas-
tase levels were associated with the failure of tamoxifen
treatment in advanced breast cancer stages, indicating a pre-
sumable interference of HNE with growth factors or their
receptors (Foekens et al., 2003b). Hence, an effective inhi-
bition of elastase by EcTI as shown here in vitro might be
important for the studies on the involvement of this protein-
ase on recurrence and progression of tumor.
Taking the interaction of HNE with the uPA/PAR/PAI-1
system into account which significantly contributes to the
generation of the potent ECM-degrading plasmin as a further
important mediator of tumor cell invasion and metastasis
(Janicke et al., 2001; Duffy and Duggan, 2004), the simul-
taneous inhibition of HNE and plasmin by EcTI can render
the tumor cell antiproliferative effect of this plant-derived
inhibitor. As the gelatinases MMP-2 and MMP-9 are mainly
expressed and secreted as zymogens requiring activation by
serine or cysteine proteinases or already active MMPs (Sha-
mamian et al., 2001), we were interested to evaluate whether
EcTI is able to interfere directly or indirectly with the acti-
vation of these gelatinases in comparison to aprotinin and
additional plant-derived serine proteinase inhibitors. HT1080
fibrosarcoma cells which released 94-kDa proMMP-9, 72-
kDa proMMP2, and small amounts of active 66-kDa MMP-
2 as previously shown by others (Moll et al., 1990) were
used for this studies. Addition of PMA stimulated the for-
mation of 66-kDa MMP-2 confirming former data of Stanton
and colleagues who demonstrated MT1-MMP to be respon-
sible for this step (Stanton et al., 1998). Our finding that
EcTI completely blocked this PMA-evoked proMMP-2 acti-
vation suggests a possible direct interaction of EcTI with
MT1-MMP activity and/or expression. This influence seems
to be independent of serine proteinases, because aprotinin as
a general serine proteinase inhibitor did not show a similar
effect. When plasminogen was added to HT1080 cells, 66-
kDa MMP-2 was entirely transformed into 64-kDa MMP-2.
Our data are in agreement with previous results of others,
suggesting a two-step model of proMMP-2 activation. In a
first step, MT1-MMP on the cell surface mediates activation
proMMP-2 into 66-kDa MMP-2 which is then released from
the cells (Nagase et al., 2006). In a second step, plasmin
derived from the cell-associated activation of plasminogen
by the uPA/PAR system can further process intermediate 66-
kDa MMP-2 into fully active 64-kDa MMP-2 (Baramova et
al., 1997). Interestingly, we found that EcTI efficiently inhib-
ited the formation of both 66-kDa and 64-kDa MMP-2 under
PMA/plasminogen-stimulating conditions, whereas aprotinin
could only block transformation into 64-kDa MMP-2 but,
similar to aprotinin EcTI, decreases the plasminogen-induced
proMMP-9 activation approving direct inhibition of plasmin
by the plant inhibitor. By contrast, neither the plant-derived
elastase/cysteine proteinase inhibitor BbCI nor the kallikrein
inhibitor BbKI (Oliva et al., 2001; Araujo et al., 2005)
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showed any effect on the proMMP-2 and -9 activation, indi-
cating that the respective target serine proteinases do not
interact with the MMP system in our cell model.
It is of special interest that whereas 5-FU massively cuts
down the proliferation rates of hMSCs already at low con-
centrations, EcTI, even at high doses, did not affect hMSC
proliferation, which indicates that it is a good candidate for
a selective tumor therapy approach without affecting the
regenerative capacity of the hMSC compartment. In conclu-
sion, our findings provide first evidence that EcTI is capable
of blocking the activation of proMMP-2 and -9 suggesting
its potential usefulness in therapeutic applications aimed to
target MMP-mediated tumor growth and invasion.
Materials and methods
Inhibitor purification
The inhibitor was purified with some modifications according to a
method described previously (Batista et al., 1996). Briefly, Entero-
lobium contortisiliquum seeds (Figure 1) were swollen in 0.15 M
NaCl 1:40 (w/v) and homogenized in a blender. The proteins in the
crude extract after centrifugation at 4000 g were precipitated by
acetone (80% v/v) at 48C. Thereafter, the sediment was separated
by centrifugation, dried under vacuum, and dissolved in 0.05 M Tris-
HCl buffer, pH 8.0. The soluble fraction was applied onto a DEAE-
Sephadex column (2=25 cm) equilibrated with 0.1 M Tris-HCl
buffer, pH 8.0. After extensive washing with the equilibrium buffer,
the inhibitor was eluted with 0.15 M NaCl in the same buffer and
the protein was verified by absorbance measurement at 280 nm.
Furthermore, the trypsin inhibitory activity was determined using
1 mM a-benzoyl-D-L-arginine-p-nitroanilide (BAPA) as substrate
(Batista et al., 1996). The fractions containing trypsin inhibitory
activity were pooled and applied in a trypsin-Sepharose resin and
subsequently on gel filtration chromatography in a Superdex 75 col-
umn equilibrated with 0.05 M Tris-HCl buffer, pH 8.0, using an
A¨ KTA Purifier (GE Healthcare, Uppsala, Sweden).
Proteinase inhibition assays
The effect of EcTI on the proteolytic activity of HNE (Sigma Chem-
ical Company, St. Louis, MO) was assayed with the specific peptide
substrates MeO-Suc-Ala-Ala-Pro-Val-pNan (Calbiochem, San Die-
go, CA, USA). The assays were performed in a 96-well plate in a
final volume of 250 ml per well at 378C using 28 nM HNE (in
0.05 M Tris-HCl, containing 0.5 M NaCl at pH 7.0 and with 11.0 mM
MeO-Suc-Ala-Ala-Ala-pNan). The inhibitor EcTI was applied in
concentrations ranging from 20 nM to 100 nM and Kiapp was deter-
mined as described (Araujo et al., 2005; Sumikawa et al., 2006).
Studies on proMMP activation
The influence of EcTI in comparison to other serine proteinase
inhibitors such as Bauhinia bauhinioides kallikrein inhibitor (BbKI)
(Oliva et al., 2001) and cysteine inhibitor (BbCI) (de Oliveira et al.,
2001) or aprotinin (Dani et al., 1963) on secretion and activation of
proMMPs was analyzed using the HT1080 fibrosarcoma cell model
(Moll et al., 1990). Briefly, HT1080 cells were incubated at 378C
under serum-free conditions in the absence and presence of 25 ng/
ml phorbol 12-myristate 13-acetate (PMA) which stimulates
proMMP expression. Furthermore, plasminogen (10 mg/ml) was
applied as a proMMP activator after being converted to plasmin by
the cell-associated uPA/PAR system. In addition, cells were simul-
taneously incubated with and without EcTI, BbCI, BbKI, or apro-
tinin (1 mM each). After 48 h culture, supernatants were collected
and analyzed for the presence of (pro)MMP-2 and (pro)MMP-9 by
gelatin zymography. Two independent experiments were performed.
Cell viability was determined by the ability of the cells to exclude
trypan blue.
Cell cultivation
The following human cancer cell lines were purchased from ACCT
(ATCC, Minnesota, USA) and cultured in RPMI 1640 (Gibco BRL/
Life Technology, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (Sigma Chemical Company), 100 mg/ml streptomy-
cin, and 100 IU/ml penicillin at 378C in an atmosphere of 5% CO2:
HCT116 and HT-29 (colorectal cancer), SkBr-3 and MCF-7 (breast
cancer), HT 1080 (fibrosarcoma), as well as K562 (chronic myeloid
leukemia in blast crisis) and THP-1 (acute monocytic leukemia).
Human primary culture of fibroblasts isolated from amniotic fluid
was kindly donated by Prof. Walter Pinto Jr. (Campinas, Brazil) and
used between passages 3 and 6. The cells were maintained in
DMEM medium (Gibco BRL/Life Technology) supplemented with
10% fetal bovine serum (Sigma Chemical Company), 2 mM L-glu-
tamine, 100 mg/ml streptomycin, and 100 IU/ml penicillin at 378C
in an atmosphere of 5% CO2.
Cryopreserved hMSCs were purchased from Cambrex (Walkers-
ville, MD, USA). The cultivation of hMSCs was performed in
aMEM medium supplemented with 16.5% fetal bovine serum and
100 IU/ml penicillin/streptomycin. Cells were grown at 378C in a
humidified atmosphere containing 95% air and 5% CO2 according
to the supplier’s instructions. Medium was refreshed twice a week
and cells were used for further cultivation or cryopreservation prior
to reaching confluence. hMSCs were used at the 5th or 6th passage
of cultivation and stem cell features were assessed by differentiation
into various mesodermal lineages as previously described (Hoelters
et al., 2005).
MTS cell viability assay
To evaluate cell viability, tumor cells and fibroblasts, respectively,
were preincubated 24 h (for fast-growing cell lines 4=103 cells/
100 ml/well) or 48 h (for slow-growing cell lines 8=103 cells/100
ml/well) in 96-well plates (Costar, Corning Incorporated, New York,
USA) at 378C in an atmosphere of 5.0% CO2. After these times,
EcTI and the chemotherapeutic drug 5-FU were added in a concen-
tration range of 1.0–12.5 mM and incubated for a further 24 h and
48 h. Thereafter, cell viability was determined with MTS (Promega,
Madison, WI, USA) and phenazine methosulfate (PMS; Sigma)
according to the method described previously (Chao and Chu,
2004). The tetrazolium salt MTS undergoes a color change caused
by its bioreduction into a water-soluble formazan. This conversion
is accomplished by dehydrogenases present in active mitochondria
and occurs as such only in living cells. The quantity of formazan
measured by light absorbance is directly proportional to the number
of living cells. In detail, MTS (2 mg/ml; pH 6.5) and PMS (3 mM)
were dissolved in PBS, filter-sterilized, and stored at -208C in light-
protected containers. To enhance the cellular reduction of MTS,
PMS was combined with MTS in a 20:1 ratio immediately before
use. Each cell-containing well of the 96-well plate was supple-
mented with 20 ml of MTS/PMS solution and incubated at 378C in
a humidified 5% CO2 atmosphere for 3 h. The absorbance was read
at 490 nm using a spectrophotometer (SpectraCount model from
Packard, Perkin Elmer, California, USA). Every cell set was ana-
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lyzed in triplicate. Data were recorded manually and calculated with
the Microsoft Excel program.
CyQuant cell proliferation assay
To study the influence of EcTI and 5-FU on hMSC proliferation,
64 000 cells were seeded into each cavity of a 6-well plate (Nunc,
Roskilde, Denmark) containing 2 ml aMEM medium supplemented
with 16.5% fetal bovine serum and 100 IU/ml penicillin/strepto-
mycin solution. Then, 24 h later medium was refreshed and two
different concentrations (10 mM and 100 mM) of EcTI or 5-FU were
added. After 7 days of incubation, the proliferation capacity of
hMSCs was assayed via binding of a fluorescent dye to cellular
nucleic acids using the CyQuant cell proliferation assay kit (Molec-
ular Probes, Eugene, OR, USA) according to the manufacturer’s
protocol. Briefly, for fixation cells were washed in PBS and stored
at -808C until further processing. After thawing, cell lysis was per-
formed in 250 ml lysis buffer. Two 100 ml aliquots of each cell set
were transferred into the cavities of a 96-well microtiter plate (Corn-
ing Costar, New York, NY, USA) and mixed with 100 ml of cell
lysis buffer containing CyQuant GR dye. After 5 min of incubation,
fluorescence was measured using a fluorescence microtiter plate
reader (HTS 7000 Bio Assay Reader; Perkin Elmer, California,
USA) at 480 nm excitation and 530 nm emission. For each exper-
iment, a standard calibration curve was generated by plotting the
measured fluorescence values of the samples versus the respective
cell number that had been determined before using a
hematocytometer.
Statistics
Experiments were performed at least three times and data are shown
as mean"SD. Student’s t-test was used to determine significance.
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